Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...

Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG.

So far in 2026, CMS has handed out 55,981 deficiencies to skilled nursing facilities across the nation. Becker’s collected a report on all of the deficiencies given by CMS in 2026 at freestanding and ...

Vitamin D rarely gets the attention it deserves. Despite being one of the most widely useful nutrients the human body relies on, deficiency remains startlingly common—and the fallout can be ...

Feeling constantly drained might not just be about poor sleep or working too hard. Researchers in Japan found that low levels of key vitamins — especially vitamin B12 and folate — may quietly ...

We may receive a commission on purchases made from links. When you first look at them, the most noticeable difference between LG's G5 and C5 smart TVs is easily their price tags. Depending on the size ...

Texas state regulators found nearly two dozen deficiencies in the emergency operations plan submitted in Camp Mystic's bid to reopen less than a year after 27 children and counselors were killed in a ...

Welcome to Regeneron's conference call to discuss its C5 Complement Development Program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this ...

Cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), met both its primary and a key secondary endpoint in the phase III NIMBLE trial of ...